These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacology of appetite suppression. Halford JC; Blundell JE Prog Drug Res; 2000; 54():25-58. PubMed ID: 10857385 [TBL] [Abstract][Full Text] [Related]
3. Pharmacology of appetite suppression: implication for the treatment of obesity. Halford JC Curr Drug Targets; 2001 Dec; 2(4):353-70. PubMed ID: 11732637 [TBL] [Abstract][Full Text] [Related]
4. Systems and interactions: an approach to the pharmacology of eating and hunger. Blundell JE Res Publ Assoc Res Nerv Ment Dis; 1984; 62():39-65. PubMed ID: 6695116 [No Abstract] [Full Text] [Related]
5. The development of tolerance to drugs that suppress food intake. Fernstrom JD; Choi S Pharmacol Ther; 2008 Jan; 117(1):105-22. PubMed ID: 17950459 [TBL] [Abstract][Full Text] [Related]
6. Neuropharmacology of human appetite expression. Halford JC; Harrold JA Dev Disabil Res Rev; 2008; 14(2):158-64. PubMed ID: 18646016 [TBL] [Abstract][Full Text] [Related]
7. The clinical pharmacology of appetite suppressant drugs. Silverstone T; Goodall E Int J Obes; 1984; 8 Suppl 1():23-33. PubMed ID: 6242052 [TBL] [Abstract][Full Text] [Related]
8. 5-HT(2C) receptor agonists and the control of appetite. Halford JC; Harrold JA Handb Exp Pharmacol; 2012; (209):349-56. PubMed ID: 22249823 [TBL] [Abstract][Full Text] [Related]
10. D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell. Kalyanasundar B; Perez CI; Luna A; Solorio J; Moreno MG; Elias D; Simon SA; Gutierrez R J Neurophysiol; 2015 Jul; 114(1):585-607. PubMed ID: 25972577 [TBL] [Abstract][Full Text] [Related]
11. The anorectic action of peripherally administered 5-HT is enhanced by vagotomy. Fletcher PJ; Burton MJ Physiol Behav; 1985 Jun; 34(6):861-6. PubMed ID: 4059374 [TBL] [Abstract][Full Text] [Related]
12. Neuroregulators and feeding: implications for the pharmacological manipulation of hunger and appetite. Blundell JE Rev Pure Appl Pharmacol Sci; 1982; 3(4):381-462. PubMed ID: 6137866 [No Abstract] [Full Text] [Related]
13. The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. McLaughlin PJ; Winston KM; Limebeer CL; Parker LA; Makriyannis A; Salamone JD Psychopharmacology (Berl); 2005 Jul; 180(2):286-93. PubMed ID: 15948012 [TBL] [Abstract][Full Text] [Related]
14. Two novel paradigms for the simultaneous assessment of conditioned taste aversion and food intake effects of anorexic agents. Benoit SC; Air EL; Wilmer K; Messerschmidt P; Hodge KM; Jones MB; Eckstein DM; McOsker CC; Seeley RJ; Woods SC; Sheldon RJ Physiol Behav; 2003 Sep; 79(4-5):761-6. PubMed ID: 12954420 [TBL] [Abstract][Full Text] [Related]
15. Effect of anorexic drugs on food intake and the micro-structure of eating in human subjects. Rogers PJ; Blundell JE Psychopharmacology (Berl); 1979 Nov; 66(2):159-65. PubMed ID: 119258 [TBL] [Abstract][Full Text] [Related]
16. Appetite suppressants. A review. Silverstone T Drugs; 1992 Jun; 43(6):820-36. PubMed ID: 1379155 [TBL] [Abstract][Full Text] [Related]